Carisma Therapeutics Inc. share price logo

Carisma Therapeutics Inc.

NASDAQ: CARM

Small Cap

as on

Carisma Therapeutics Inc. Stock Performance

as on May 28, 2026 at 5:45 am IST

  • $0.01
    $0.01
  • $0.00
    $1.27

Carisma Therapeutics Inc. share price movements today

Previous Close
-
Open
$0.01
Volume
388.0K
Day's Low - High
$0.01 - $0.01
52 Week Low - High
$0.00 - $1.27

Carisma Therapeutics Inc. Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Carisma Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Carisma Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.2K

EPS (TTM)

-0.69

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

Industry PE ratio

-3.3629856850715747

PEG Ratio

0

EBITDA

14.2M

Revenue (TTM)

52.6M

Profit Margin

15.28%

Return On Equity TTM

-362.79%

Carisma Therapeutics Inc. Stock Valuation

Track how Carisma Therapeutics Inc. P/E has moved over time to understand its valuation trends.

Carisma Therapeutics Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-4.46x)

June 30, 2023

Industry (-3.36x)

May 27, 2026

Today (0.00x)

May 27, 2026

Highest (1.10x)

September 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 0.00x

Carisma Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Carisma Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Carisma Therapeutics Inc. image
Carisma Therapeutics Inc.
BUY$4.2KNANA15.28%NA
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.7B110.73%74.5512.55%NA
BeiGene, Ltd. image
BeiGene, Ltd.
NA$31.4BNA68.438.94%NA
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.3B110.28%25.7735.51%NA
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$67.0B28.12%15.629.65%0.5599999999999999%

Analyst Recommendation on Carisma Therapeutics Inc. Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Carisma Therapeutics Inc.. Average target price of $1

Carisma Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Carisma Therapeutics Inc..

What analysts predicted

100%UPSIDE

Target Price

$1

Current Price

$

Analyzed by

12 Analysts

Target

$1.00

Carisma Therapeutics Inc. target price $1, a slight upside of 100% compared to current price of $. According to 12 analysts rating.

Carisma Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
3
3
4
3
9
3
3
3
-
45
Gross Profit
-14
-15
-
-14
-6
3
2
3
0
45
Operating Income
-20
-22
-22
-19
-11
-13
-17
-9
-5
43
EBITDA
-20
-21
-
-17
-11
-12
-16
-8
-5
44
Interest Expense
-
-
-
0
0
-
-
-
-
-
Depreciation
0
0
0
1
0
0
0
0
-
-
Income Before Tax
-19
-21
-21
-18
-11
-12
-17
-9
-9
44
Income Tax Expense
0
0
-
0
-
-
-
-
-
-
Net Income
-19
-21
-20
-18
-11
-12
-17
-9
-9
44
Net Profit Margin
-558.31%
-559.26%
-488.65%
-558.67%
-121.37%
-375.24%
-482.75%
-248.48%
0.00%
98.82%

Carisma Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
0
29
0
11
26
9
14
19
Gross Profit
0
29
0
11
26
9
-59
-40
Operating Income
-35
6
-19
-28
-28
-56
-88
-62
EBITDA
-31
2
-28
-27
-8
-56
-85
-56
Interest Expense
1
0
-
1
8
3
1
-
Depreciation
-
-
-
0
0
1
2
3
Income Before Tax
-33
1
-29
-28
-8
-61
-86
-60
Income Tax Expense
1
0
-
0
-8
-3
8
-60
Net Income
-33
1
-29
-28
0
-61
-86
-60
Net Profit Margin
-3378.99%
6.31%
-6830.35%
-252.31%
-1.27%
-622.60%
-582.34%
-308.05%

Carisma Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-21
-20
-18
-11
-12
-17
-9
-9
44
Operating Cash Flow
-20
-16
-22
-16
-13
-8
-10
-5
1
Investing Cash Flow
29
-
0
0
-56
-
0
0
-
Financing Cash Flow
-2
0
1
0
0
0
0
-
-1
Change in Cash
6
-5
-21
-16
-13
-8
-10
-5
0

Carisma Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
1
-29
-33
-107
-28
-40
-61
-86
-60
Operating Cash Flow
2
-17
-22
-37
-27
-37
-7
-81
-59
Investing Cash Flow
0
0
0
0
0
-1
-32
72
0
Financing Cash Flow
-13
7
58
35
72
15
35
62
0
Change in Cash
-10
-10
35
-2
44
-23
-138
53
-59

Insights on Carisma Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 3.38M → 3.72M (in $), with an average increase of 4.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.8% return, outperforming this stock by 157.0%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CARM stock has moved down by -83.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -9.26M → -9.77M (in $), with an average decrease of 5.5% per quarter

About Carisma Therapeutics Inc.

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
OrganisationCarisma Therapeutics Inc.
Headquarters3675 Market Street, Philadelphia, PA, United States, 19104
IndustryBiotechnology
CEODr. Saar Gill M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Carisma Therapeutics Inc.

Name

Title

Dr. Saar Gill M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Ms. Natalie McAndrew

Vice President of Finance

FAQs

What is Carisma Therapeutics Inc.'s market capitalisation today?

Carisma Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Carisma Therapeutics Inc. Stock (CARM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Carisma Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Carisma Therapeutics Inc. Shares .

What is the minimum amount required to buy Carisma Therapeutics Inc. Stock (CARM) from India?

Indian investors can start investing in Carisma Therapeutics Inc. (CARM) shares with as little as ₹95.69 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.90 in Carisma Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Learn more about fractional shares .